India - Glenmark Pharmaceuticals Limited (Glenmark), an integrated, research-led, global pharmaceutical company, today announced its financial results for the first quarter ended June 30, 2023.

For the first quarter of FY 2023 24, Glenmark's consolidated revenue was at Rs. 34,016 Mn as against Rs. 27,773 Mn recording an increase of 22.5% YoY. EBITDA was at Rs. 6,312 Mn in the quarter ended June 30, 2023 as against Rs. 4,316 Mn in the previous corresponding quarter, registering an increase of 46.2% YoY. Profit After Tax (PAT) for the first quarter of FY 2023 24 was at Rs. 1,731 Mn.

We had yet another strong quarter both in terms of revenue and operating margins. The robust growth in sales was led by our branded markets in RoW region. Our Europe business performed significantly well on the back of a strong generics portfolio and continued gains in marketshare, in our leading respiratory brands. Our North America businessremained stable, and our India business continued to significantly outperform industry growth rates. We also had our GHG emission targets certified by the Science Based Targets initiative (SBTi) giving us an impetus to further pursue our ESG goals, while also benchmarking us at a global scale.' said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Ltd. He further added, 'Going forward our goal remains to sustain the momentum, as RYALTRIS continues to meaningfully contribute across all the covered markets. We also remain on track to achieve our objectives for FY24.

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an integrated, research led, global pharmaceutical company, with a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 10 world class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2021; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2021. The company has also been Great Place To Work Certified in India. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), becoming the second Indian Pharmaceuticals company to achieve this approval. The organization has impacted over 2.9 million lives over the last decade through its CSR interventions.

Contact:

Udaykumar Murthy

Tel: +91 9960377617

Email: corpcomm@glenmarkpharma.com

(C) 2023 Electronic News Publishing, source ENP Newswire